Aptose Biosciences’ (APTO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Aptose Biosciences in a report on Wednesday, January 8th. They set a “hold” rating on the stock.

Aptose Biosciences Stock Performance

Shares of NASDAQ:APTO opened at $0.22 on Friday. The firm has a market capitalization of $13.24 million, a PE ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.48. The firm has a fifty day moving average of $0.25 and a 200 day moving average of $0.40.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.